Oxeia Biopharmaceuticals, Inc. (OXEA)

Oxeia Biopharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-1.97M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Price Targetn/a
Earnings Daten/a

About OXEA

Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Our first two indications are for (i) mild traumatic brain injury, known as concussion, and (ii) the cognitive decline, lethargy and “brain-fog” associated with Covid-19 infection, known as Covid Longhauler syndrome (“Long Covid”). On May 1, 2017, we acquired certain rights to a ghrelin molecule OXE103 that was originally developed by Daiichi ...

IndustryHealth Care
CEODr. Michael Wyand
Stock ExchangeNASDAQ
Ticker SymbolOXEA
Full Company Profile

Financial Performance

Financial Statements


Oxeia Biopharmaceuticals IPO Registration Document (S-1)

Oxeia Biopharmaceuticals has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC